Zydus Lifesciences Unit Buys 5.9% Stake in Agenus for $16 Million

MT Newswires Live

2025/06/04

Zydus Lifesciences Ltd (BOM:532321, NSE:ZYDUSLIFE) wholly owned subsidiary, Zynext Ventures USA LLC, acquired a 5.9% stake in US-based immuno-oncology company Agenus Inc, according to a Tuesday filing on the local bourse.

The purchase of 2.13 million shares cost approximately $16 million at $7.50 per share.

Agenus develops next-generation immunotherapies, including Botensilimab and Balstilimab, which are in advanced clinical trials for multiple cancer types. The investment aims to accelerate these programmes and expand their application in earlier treatment stages.

The deal is subject to regulatory approvals, including those under US antitrust and foreign investment laws. Zynext Ventures plans to complete the acquisition within 60 days, with a possible 30-day extension.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540882820"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540882820\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540882820?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 07:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540882820","market":"fut","top_or_hot":-1,"title":"Zydus Lifesciences Unit Buys 5.9% Stake in Agenus for $16 Million","media":"MT Newswires Live","content":"<html><body><p> Zydus Lifesciences Ltd (BOM:532321, NSE:ZYDUSLIFE) wholly owned subsidiary, Zynext Ventures USA LLC, acquired a 5.9% stake in US-based immuno-oncology company Agenus Inc, according to a Tuesday filing on the local bourse.</p><p>The purchase of 2.13 million shares cost approximately $16 million at $7.50 per share.</p><p>Agenus develops next-generation immunotherapies, including Botensilimab and Balstilimab, which are in advanced clinical trials for multiple cancer types. The investment aims to accelerate these programmes and expand their application in earlier treatment stages.</p><p>The deal is subject to regulatory approvals, including those under US antitrust and foreign investment laws. Zynext Ventures plans to complete the acquisition within 60 days, with a possible 30-day extension.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zydus Lifesciences Unit Buys 5.9% Stake in Agenus for $16 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZydus Lifesciences Unit Buys 5.9% Stake in Agenus for $16 Million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-06-04 07:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Zydus Lifesciences Ltd (BOM:532321, NSE:ZYDUSLIFE) wholly owned subsidiary, Zynext Ventures USA LLC, acquired a 5.9% stake in US-based immuno-oncology company Agenus Inc, according to a Tuesday filing on the local bourse.</p><p>The purchase of 2.13 million shares cost approximately $16 million at $7.50 per share.</p><p>Agenus develops next-generation immunotherapies, including Botensilimab and Balstilimab, which are in advanced clinical trials for multiple cancer types. The investment aims to accelerate these programmes and expand their application in earlier treatment stages.</p><p>The deal is subject to regulatory approvals, including those under US antitrust and foreign investment laws. Zynext Ventures plans to complete the acquisition within 60 days, with a possible 30-day extension.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2540882820","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540882820","pubTimestamp":1748992743,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zydus Lifesciences Ltd  wholly owned subsidiary, Zynext Ventures USA LLC, acquired a 5.9% stake in US-based immuno-oncology company Agenus Inc, according to a Tuesday filing on the local bourse.The purchase of 2.13 million shares cost approximately $16 million at $7.50 per share.Agenus develops next-generation immunotherapies, including Botensilimab and Balstilimab, which are in advanced clinical trials for multiple cancer types. The investment aims to accelerate these programmes and expand their application in earlier treatment stages.The deal is subject to regulatory approvals, including those under US antitrust and foreign investment laws. Zynext Ventures plans to complete the acquisition within 60 days, with a possible 30-day extension.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AGEN":"艾吉纳斯公司"},"translate_title":"Zydus Lifesciences部门以1600万美元收购Agenus 5.9%的股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":1},"content_text":"Zydus Lifesciences Ltd (BOM:532321, NSE:ZYDUSLIFE) wholly owned subsidiary, Zynext Ventures USA LLC, acquired a 5.9% stake in US-based immuno-oncology company Agenus Inc, according to a Tuesday filing on the local bourse.The purchase of 2.13 million shares cost approximately $16 million at $7.50 per share.Agenus develops next-generation immunotherapies, including Botensilimab and Balstilimab, which are in advanced clinical trials for multiple cancer types. The investment aims to accelerate these programmes and expand their application in earlier treatment stages.The deal is subject to regulatory approvals, including those under US antitrust and foreign investment laws. Zynext Ventures plans to complete the acquisition within 60 days, with a possible 30-day extension.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}